Loading…
Drug interaction
A major drug-drug interaction between Upadacitinib and Ocrelizumab is recorded in public interaction data. Severity reflects the source classification; it does not describe your individual risk. Do not start, stop, or change either medicine based on this page.
A major interaction can cause a clinically significant - sometimes serious - effect. Prescribers usually avoid this combination, or use it only with close monitoring and dose adjustments.
Do not combine these on your own. If both have been prescribed, tell your pharmacist or doctor so they can confirm it is intended and watch for problems.
DDInter 2.0 (CC-BY 4.0, https://ddinter.scbdd.com)
This is not medical advice. Drugvu is an independent aggregator of public records.